limit stock-mov catalyst
downgrad ac immun neutral outperform due
limit catalyst next month import valu
driver aciu remain crenezumab partner roch
current alzheim diseas lower target price
shift timelin potenti approv launch
studi read posit would
think share remain range-bound get data
readout crenezumab biogen aducanumab studi
key read-through expect interim studi year
key aciu catalyst major upsid remain year away
studi crenezumab ac immun
note data expect respect
remain posit crenezumab asset believ pivot
studi success asset clearli multibillion dollar
potenti estim peak sale crenezumab vs
previous sinc slow ramp year result royalti
aciu keep probabl success revenu
ac immun program beyond crenezumab program
remain earli partnership small molecul could upsid risk
thesi program anti-ptau vaccin
develop alzheim janssen anti-abeta vaccin
develop syndrom
key upsid risk thesi earli clinic success crenezumab
pipelin asset downsid risk includ clinic failur
valuat metric
number share
outperform neutral
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
ac immun biotechnolog compani focus
develop therapi diagnosi treatment
alzheim diseas neurodegen diseas
price rate outperform neutral target price analyst
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
higher probabl success due better safeti profil
lead much higher dosag phase mg/kg
multipl bind capac monom oligom fibril
lower probabl success seen limit data
higher dose make claim compani
downgrad ac immun neutral outperform due limit
catalyst next month import valu driver ac immun
remain crenezumab partner roch current alzheim
diseas lower target price shift timelin
potenti approv launch studi read posit
would earlier program like still remain earli
expect major efficaci data next month
overal think share remain range-bound get data readout
crenezumab biogen aducanumab studi key read-through
expect interim studi year therefor key aciu
catalyst major upsid remain year away upsid risk thesi
around clinic success crenezumab downsid risk includ clinic failur
shift crenezumab launch timelin us europ
base current progress studi crenezumab
ac immun note data expect
respect data posit could scenario
compani could file first studi expect high stat sig
result would provid signific upsid share previous
aggress timelin assum use first studi file reach full
enrol around mid-jan timelin remain track like
readout estim efficaci endpoint year expect
aducanumab program could read around late
remain posit crenezumab asset believ pivot studi
success asset clearli multibillion dollar potenti estim
peak sale crenezumab vs previous sinc slow
ramp year ac immun get high singl digit mid-teen royalti
estim aciu compani revenu would vs previous
maintain probabl success unadjust revenu state
slightli lower probabl success aducanumab
ac immun program beyond crenezumab program remain
earli partnership small molecul could upsid risk thesi
program anti-ptau vaccin develop alzheim
janssen anti-abeta vaccin develop syndrom
expect learn safeti efficaci rel small studi
expect signific stock move syndrom get data low
dose cohort dose escal studi long-term program remain
import compani diversif beyond crenezumab base case
conserv assum peak get data program
think ac immun mani novel innov
program develop across neuro-spac
ac immun proprietari antibodi small molecul technolog
platform enabl develop variou asset mani notabl target
neuro-degen diseas specif antibodi vaccin
develop key target amyloid-beta tau develop proprietari
technolog addit diagnost imag small molecul platform
develop neuro-degen treatment well
figur overview aciu pipelin program
long term think ac immun well posit alzheim landscap
alzheim histor riskier therapeut area develop drug
think aciu diversifi approach multipl modal antibodi vaccin small
molecul variou target set well success larg diseas area
strateg partner leader neuro space roch
retain econom sever program program
particular interest small molecul tau enter phase year
wholli own addit compani also excit alpha-synuclein
pet tracer imag agent studi collabor
howev near term dont see catalyst materi move stock
next month think compani continu make meaning
progress expect timelin remain track compani continu
make progress next month clinic program howev dont see
meaning stock-mov event next month
figur overview program current statu
anti-amyloid beta antibodi partner roch
partner janssen
partner roch
candid tau alpha-
synuclein
wholli own
biogen
phase alzheim
data expect
phase syndrom on-going low dose
cohort complet enrol dsmb
approv plan dose higher
phase alzheim start
complet phase studi alzheim
discuss plan forward fda
enter phase
tau pet imag agent phase
small molecul tau
enter phase
sale ex-u
diagnos treat total
prodrom patient convert mild
total patient ellig ad treatment
total patient crenezumab
gross net
diagnos treat total
prodrom patient convert mild
total patient ellig ad treatment
total patient crenezumab
compani mention price
